WallStreetZenWallStreetZen

NASDAQ: ENVB
Enveric Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ENVB stock forecasts and price targets.

Forecast return on equity

Is ENVB forecast to generate an efficient return?

Company
-22.1%
Industry
22.84%
Market
326.48%
ENVB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ENVB forecast to generate an efficient return on assets?

Company
-13.61%
Industry
15.53%
ENVB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ENVB earnings per share forecast

What is ENVB's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.88
Avg 2 year Forecast
-$1.79

ENVB revenue forecast

What is ENVB's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

ENVB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENVB$6.11N/AN/A
NCEL$4.01N/AN/A
SPRC$2.75N/AN/A
AZTR$0.39N/AN/A
PBM$2.31N/AN/A
View Top Biotech Stocks

Enveric Biosciences Stock Forecast FAQ

What is ENVB's earnings growth forecast for 2025-2026?

(NASDAQ: ENVB) Enveric Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 188.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,844.38%.

Enveric Biosciences's earnings in 2025 is -$9,942,825.On average, 3 Wall Street analysts forecast ENVB's earnings for 2025 to be -$237,304, with the lowest ENVB earnings forecast at -$227,998, and the highest ENVB earnings forecast at -$244,283.

In 2026, ENVB is forecast to generate -$482,885 in earnings, with the lowest earnings forecast at -$463,949 and the highest earnings forecast at -$497,088.

If you're new to stock investing, here's how to buy Enveric Biosciences stock.

What is ENVB's revenue growth forecast for 2025-2026?

(NASDAQ: ENVB) Enveric Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,974.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,423.42%.

Enveric Biosciences's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ENVB's revenue for 2025 to be $0, with the lowest ENVB revenue forecast at $0, and the highest ENVB revenue forecast at $0.

In 2026, ENVB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ENVB's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: ENVB) forecast ROA is -13.61%, which is lower than the forecast US Biotechnology industry average of 15.53%.

What is ENVB's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ENVB) Enveric Biosciences's current Earnings Per Share (EPS) is -$126.40. On average, analysts forecast that ENVB's EPS will be -$0.88 for 2025, with the lowest EPS forecast at -$0.84, and the highest EPS forecast at -$0.90. In 2026, ENVB's EPS is forecast to hit -$1.79 (min: -$1.72, max: -$1.84).

What is ENVB's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: ENVB) forecast ROE is -22.1%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.